You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

ZAGAM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zagam, and what generic alternatives are available?

Zagam is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in ZAGAM is sparfloxacin. Additional details are available on the sparfloxacin profile page.

US Patents and Regulatory Information for ZAGAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan ZAGAM sparfloxacin TABLET;ORAL 020677-001 Dec 19, 1996 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZAGAM

See the table below for patents covering ZAGAM around the world.

Country Patent Number Title Estimated Expiration
Spain 2029786 ⤷  Try a Trial
Latvia 5501 Hinolina atvasinajumu ai to farmaceitiski pienemama estera vai farmaceitiski pienemamas hinolina atvasinajuma vai estera sals iegusanas metode ⤷  Try a Trial
European Patent Office 0375658 Dérivés de quinoléine et procédé de leur préparation. (Quinoline derivatives and processes for preparation thereof.) ⤷  Try a Trial
Denmark 170774 ⤷  Try a Trial
U.S.S.R. 1519529 CПOCOБ ПOЛУЧEHИЯ ПPOИЗBOДHOГO XИHOЛИHA, EГO ФAPMAЦEBTИЧECKИ ПPИEMЛEMOГO CЛOЖHOГO ЭФИPA ИЛИ ФAPMAЦEBTИЧECKИ ПPИEMЛEMOЙ COЛИ ПPOИЗBOДHOГO XИHOЛИHA ИЛИ CЛOЖHOГO ЭФИPA (METHOD OF PRODUCING QUINOLINE DERIVATIVES, ITS PHARMACEUTICALLY ACCEPTABLE ESTER OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS) ⤷  Try a Trial
Denmark 514586 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZAGAM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0375658 C300014 Netherlands ⤷  Try a Trial PRODUCT NAME: ORBIFLOXACIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRATION NO/DATE: NL 9652 - NL 9654 20000208
0375658 SPC/GB98/036 United Kingdom ⤷  Try a Trial PRODUCT NAME: ORBIFLOXACIN; REGISTERED: UK 00201/4035 19980608; UK 00201/4036 19980608; UK 00201/4037 19980608
0375658 25/2000 Austria ⤷  Try a Trial PRODUCT NAME: ORBIFLOXACIN; NAT. REGISTRATION NO/DATE: 8-00439, 8-00440, 8-00438 20000225; FIRST REGISTRATION: GB VM 00201/4035 - 00201/4037 19980608
0375658 2000C/020 Belgium ⤷  Try a Trial PRODUCT NAME: ORBIFLOXACINE; NAT. REGISTRATION NO/DATE: 282 IS 58 F3 20000228; FIRST REGISTRATION: GB VM00201/4036 19980608
0221463 SPC/GB95/012 United Kingdom ⤷  Try a Trial SPC/GB95/012: 20061024, EXPIRES: 20090106
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.